We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$139M
AUM Growth
-$16.2M
Cap. Flow
-$1.33M
Cap. Flow %
-0.96%
Top 10 Hldgs %
71.95%
Holding
68
New
1
Increased
14
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$967K
2
DCGO icon
DocGo
DCGO
+$753K
3
PHR icon
Phreesia
PHR
+$306K
4
GOSS icon
Gossamer Bio
GOSS
+$281K
5
NKTR icon
Nektar Therapeutics
NKTR
+$276K

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.04M
2
BMY icon
Bristol-Myers Squibb
BMY
+$806K
3
PGNY icon
Progyny
PGNY
+$755K
4
BIIB icon
Biogen
BIIB
+$544K
5
TGTX icon
TG Therapeutics
TGTX
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
2 Energy 2.82%
3 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$284M
$987K 0.71%
15,000
– –
PXD
27
DELISTED
Pioneer Natural Resource Co.
PXD
$950K 0.68%
3,800
– –
CYTK icon
28
Cytokinetics
CYTK
$11B
$920K 0.66%
25,000
– –
IMGN
29
DELISTED
Immunogen Inc
IMGN
$904K 0.65%
190,000
– –
PTGX icon
30
Protagonist Therapeutics
PTGX
$8.75B
$900K 0.65%
38,000
– –
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
$820K 0.59%
245,127
+186,667
+319% +$967K
AVEO
32
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$783K 0.56%
140,000
– –
CFRX
33
DELISTED
ContraFect Corporation
CFRX
$730K 0.53%
2,500
– –
NARI
34
DELISTED
Inari Medical, Inc. Common Stock
NARI
$725K 0.52%
8,000
+1,000
+14% +$81.8K
NKTR icon
35
Nektar Therapeutics
NKTR
$2.39B
$690K 0.5%
8,533
+1,866
+28% +$276K
IRTC icon
36
iRhythm Holdings
IRTC
$3.59B
$630K 0.45%
4,000
– –
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$610K 0.44%
12,000
– –
KALV
38
DELISTED
KalVista Pharmaceuticals
KALV
$590K 0.42%
40,000
– –
TSVT
39
DELISTED
2seventy bio
TSVT
$586K 0.42%
34,333
+6,334
+23% +$107K
VNDA icon
40
Vanda Pharmaceuticals
VNDA
$312M
$566K 0.41%
50,000
-10,000
-17% -$131K
CCXI
41
DELISTED
ChemoCentryx, Inc.
CCXI
$501K 0.36%
20,000
– –
CGEM icon
42
Cullinan Oncology
CGEM
$1.05B
$472K 0.34%
45,114
– –
SILK
43
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$413K 0.3%
10,000
+2,000
+25% +$70.4K
BLUE
44
DELISTED
bluebird bio
BLUE
$407K 0.29%
4,200
– –
ZNTL icon
45
Zentalis Pharmaceuticals
ZNTL
$308M
$369K 0.27%
8,000
– –
FOLD
46
DELISTED
Amicus Therapeutics
FOLD
$360K 0.26%
38,000
– –
VTYX
47
DELISTED
Ventyx Biosciences
VTYX
$339K 0.24%
25,000
– –
XNCR icon
48
Xencor
XNCR
$1.44B
$328K 0.24%
12,300
– –
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.37B
$325K 0.23%
20,000
– –
STOK icon
50
Stoke Therapeutics
STOK
$1.82B
$316K 0.23%
15,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Birchview Capital held 68 positions worth $139M, down 10% from $155M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Birchview Capital's Q1 2022 filing shows 1 new, 14 increased, 5 reduced and 5 closed positions. Its largest new stake was Phreesia: 10,000 shares worth $264K. The largest sale was Arena Pharmaceuticals Inc, an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2022 buy was Phreesia: 10,000 shares worth $264K.
  • Birchview Capital added most to Soleno Therapeutics in Q1 2022, an estimated $967K increase.
  • Birchview Capital's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $806K.
  • Birchview Capital fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $2.04M.
  • Birchview Capital's ten largest holdings make up 72% of its $139M portfolio in Q1 2022.
  • Birchview Capital opened 1 new position and closed 5 in Q1 2022.
  • Birchview Capital's portfolio value fell 10% quarter-over-quarter to $139M.

Based on Birchview Capital's 13F filing for Q1 2022, filed 13 May 2022.